上海之江生物科技股份有限公司 董事会议事规则 上海之江生物科技股份有限公司 董事会议事规则 第一条 宗旨 为了保护上海之江生物科技股份有限公司（以下简称"公司"）和股东的权 益，规范董事的行为，建立规范化的董事会组织架构及运作程序，保障公司经营 决策高效、有序地进行，依照《中华人民共和国公司法》《中华人民共和国证券 法》等有关法律法规以及《上海之江生物科技股份有限公司章程》（以下简称"《公 司章程》"）的规定，制定本规则。 第二条 董事会办公室 董事会下设董事会办公室，处理董事会日常事务。 董事会秘书兼任董事会办公室负责人，保管董事会和董事会办公室印章。 第三条 定期会议 董事会会议分为定期会议和临时会议。 董事会每年度至少召开两次会议。 第四条 定期会议的提案 （四）独立董事提议，且经全体独立董事过半数同意时； （五）《公司章程》规定的其他情形。 在发出召开董事会定期会议的通知前，董事会办公室应当充分征求各董事的 意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总经理和其他高级管理人员的意见。 第五条 临时会议 有下列情形之一的，董事会应当召开临时会议： （一）代表 1/10 以上 ...

第一条 为规范公司对外担保管理，规范公司担保行为，控制公司经营风险， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所科创 板股票上市规则》《上市公司监管指引第 8 号——上市公司资金往来、对外担保 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》、《上海之江生物科技股份有限公司章程》（以下简称"《公司章程》"）及其他 有关法律、法规的规定，制定本制度。 第二条 本制度所述的对外担保是指公司为他人提供的担保，包括公司对控 股子公司的担保。公司及控股子公司的对外担保总额，是指包括公司对控股子公 司担保在内的公司对外担保总额与公司控股子公司对外担保总额之和。 第三条 公司对外担保应当遵循安全、平等、自愿、公平、诚信、互利的原 则。公司有权拒绝任何强令其为他人提供担保的行为。 第四条 公司对外担保管理实行多层审核制度，所涉及的公司相关部门包括： 财务部门为公司对外担保的初审及日常管理部门，负责受理及初审所有被担保人 提交的担保申请以及对外担保的日常管理与持续风险控制；董事会秘书办公室负 责公司对外担保的合规性复核、组织履行董事会或股东会的审批程序。 上海之江生物科 ...

广发价值核心混合A（010377）成立日期2021年1月22日，最新规模35.16亿。今年以来收益68.54%，同 类排名147/8194；近一年收益114.67%，同类排名129/7963；成立以来亏损0.78%。 广发价值核心混合A（010377）基金经理为吴远怡。 截至发稿，吴远怡累计任职时间4年333天，现任基金资产总规模204.78亿元，任职期间最佳基金回报 113.46%， 任职期间最差基金回报-17.06%。 8月27日，之江生物跌5.13%，截至发稿，报25.71元/股，成交2.01亿元，换手率3.94%，总市值49.40亿 元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒82.71%，其它10.54%，分子诊断仪器5.00%，其他(补充)1.75%。 从之江生物十大流通股东角度 数据显示，广发基金旗下1只基金位居之江生物十大流通股东。广发价值核心混合A（010377）一季度 持有股数481.72万股， ...

之江生物首次公开发行募集资金总额为210,378.05万元，募集资金净额为194,232.16万元，较原计划多 58,643.05万元；公司2021年1月12日披露招股书显示，公司拟募集资金135,589.11万元，计划用于体外诊 断试剂生产线升级项目、分子诊断工程研发中心建设项目、营销与服务网络升级项目、产品研发项目、 补充流动资金。 之江生物首次公开发行的发行费用总额为16,145.89万元，其中，保荐及承销费用为14,495.05万元。 之江生物于2021年1月18日在上交所科创板上市，发行数量为48,676,088股，发行价格为43.22元/股，保 荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为王莉、 陈邦羽。 上市首日，之江生物收报74.88元，上市第六个交易日，之江生物盘中最高报93.80元。 中国经济网北京8月26日讯之江生物(688317.SH)今日收报27.10元，跌幅6.49%，总市值52.07亿元。目前 该股处于破发状态。 ...

Core Viewpoint - Zhijiang Biotechnology experienced a 5% decline in stock price, currently trading at 27.53 CNY per share, with a market capitalization of 5.29 billion CNY [1] Company Overview - Shanghai Zhijiang Biotechnology Co., Ltd. was established on April 18, 2005, and went public on January 18, 2021. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes: 82.71% from nucleic acid testing kits, 10.54% from other products, 5.00% from molecular diagnostic instruments, and 1.75% from other sources [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Zhijiang Biotechnology, holding 909,200 shares, which represents 0.47% of the circulating shares. The fund has incurred an estimated floating loss of approximately 1.32 million CNY today [2] - Dazhong Jingheng Mixed A was established on June 15, 2012, with a current scale of 397 million CNY. Year-to-date returns are 37.41%, ranking 1284 out of 8194 in its category, while the one-year return is 103.51%, ranking 262 out of 7962. Since inception, the fund has achieved a return of 361.38% [2] Fund Management - The fund manager of Dazhong Jingheng Mixed A is Su Bingyi, who has a tenure of 13 years and 203 days. The total asset size of the fund is 1.24 billion CNY, with the best return during his tenure being 240.01% and the worst being -71.74% [3] Fund Holdings - Dazhong Jingheng Mixed A holds 909,200 shares of Zhijiang Biotechnology, unchanged from the previous period, accounting for 1.97% of the fund's net value, making it the sixth-largest holding. The estimated floating loss today is approximately 1.32 million CNY [4]

Group 1 - The core point of the news is that Zhijiang Bio experienced a 5% drop in stock price, currently trading at 27.53 yuan per share, with a total market capitalization of 5.29 billion yuan [1] - Zhijiang Bio, established on April 18, 2005, and listed on January 18, 2021, specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of Zhijiang Bio includes 82.71% from nucleic acid testing kits, 10.54% from other products, 5.00% from molecular diagnostic instruments, and 1.75% from other sources [1] Group 2 - Among the top circulating shareholders of Zhijiang Bio, a fund under Rongtong Fund has reduced its holdings by 200,000 shares, now holding 1.5 million shares, which represents 0.78% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 2.074 billion yuan and has achieved a year-to-date return of 24.46%, ranking 3000 out of 8194 in its category [2] - The fund has a one-year return of 48.49%, ranking 2565 out of 7962, and a cumulative return since inception of 200.7% [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 3 days [3] - The total asset scale of the fund is 4.223 billion yuan, with the best return during Wan's tenure being 163.77% and the worst being -14.89% [3]

8月20日，之江生物连续4个交易日下跌，区间累计跌幅-3.89%。上海之江生物科技股份有限公司(股票代码:688317)成立于2005年,是专业从事分子诊断试剂 及仪器设备的研发、生产和销售的高新技术企业,致力于自动化智能检测设备、各类诊断试剂、关键原材料等的开发。 财报显示，广发基金旗下广发价值核心混合A为之江生物前十大股东，今年二季度不变。今年以来收益率58.08%，同类排名178(总4493)。 广发价值核心混合A基金经理为吴远怡。 资料显示，广发基金管理有限公司成立于2003年8月，董事长为葛长伟，总经理为王凡。目前，广发基金共有9名股东，广发证券股份有限公司持股 54.53%、烽火通信科技股份有限公司持股14.19%、深圳市前海香江金融控股集团有限公司持股14.19%、广州科技金融创新投资控股有限公司持股7.09%、嘉 裕元（珠海）股权投资合伙企业（有限合伙）持股3.87%、嘉裕祥（珠海）股权投资合伙企业（有限合伙）持股2.23%、嘉裕禾（珠海）股权投资合伙企业 （有限合伙）持股1.55%、嘉裕泓（珠海）股权投资合伙企业（有限合伙）持股1.19%、嘉裕富（珠海）股权投资合伙企业（有限合伙）持股1.1 ...

中国经济网北京8月15日讯 之江生物(688317.SH)今日收报24.72元，跌幅1.90%。目前该股处于破发 状态。 之江生物于2021年1月18日在上交所科创板上市，发行数量为48,676,088股，发行价格为43.22元/ 股，保荐机构（主承销商）为海通证券股份有限公司（现名"国泰海通证券股份有限公司"），保荐代表 人为王莉、陈邦羽。 上市首日，之江生物收报74.88元，上市第六个交易日，之江生物盘中最高报93.80元。 之江生物首次公开发行募集资金总额为210,378.05万元，募集资金净额为194,232.16万元，较原计划 多58,643.05万元；公司2021年1月12日披露招股书显示，公司拟募集资金135,589.11万元，计划用于体外 诊断试剂生产线升级项目、分子诊断工程研发中心建设项目、营销与服务网络升级项目、产品研发项 目、补充流动资金。 之江生物首次公开发行的发行费用总额为16,145.89万元，其中，保荐及承销费用为14,495.05万元。 （责任编辑：关婧） ...

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

Industry Overview - On August 14, the medical device industry experienced a decline of 2.45% with a net outflow of 1.74 billion yuan in principal funds [1] - Among the component stocks, 13 increased while 87 decreased [1] Major Fund Outflows - The companies with the highest net outflows of principal funds included: - Kehua Bio (29.96 million yuan) - Baolait (29.32 million yuan) - Shangrong Medical (28.74 million yuan) - Weisi Medical (26.93 million yuan) - ST Kelly (26.25 million yuan) [1] Notable Stock Performance - Key stocks with significant movements included: - Sainuo Medical: Latest price 30.43, up 3.05%, with a net inflow of 164 million yuan (7.25% of total) [1] - Botao Bio: Latest price 45.13, up 19.99%, with a net inflow of 543.74 thousand yuan (12.47% of total) [1] - Yuyue Medical: Latest price 35.67, down 0.17%, with a net inflow of 49.30 thousand yuan (12.91% of total) [1] - Kefu Medical: Latest price 40.58, up 6.99%, with a net inflow of 470.40 thousand yuan (14.3% of total) [1] - Huatai Medical: Latest price 290.99, down 2.03%, with a net inflow of 297.47 thousand yuan (9.99% of total) [1] - Aohua Endoscopy: Latest price 49.14, down 7.79%, with a net inflow of 2363.53 thousand yuan (10.09% of total) [1] - Meihua Medical: Latest price 20.94, up 3.05%, with a net inflow of 2316.72 thousand yuan (4.81% of total) [1] - Wanfu Bio: Latest price 24.28, down 0.92%, with a net inflow of 184.26 thousand yuan (5.48% of total) [1] - Zhijiang Bio: Latest price 25.24, up 4.87%, with a net inflow of 1420.31 thousand yuan (5.07% of total) [1] - Mairande: Latest price 51.64, up 1.06%, with a net inflow of 1335.64 thousand yuan (2.42% of total) [1]